Walmsley will step down from the board of directors of GSK at the end of the year, and will step down as CEO on 30th ...

Investors were spooked by the miss, and shares in Nasdaq-listed Enanta were down around 11%, having risen sharply in ...

Already a blockbuster therapy for advanced breast cancer and other indications like gastric cancer, Enhertu made revenues of ...

At this year’s LSX World Congress in Boston, an entire track was devoted to Obesity Science and Innovation, with pharma ...

Antibody specialist Genmab has continued its shift from out-licensing drugs to developing its own medicines with a deal to ...

AstraZeneca is the latest big pharma group to open up a Direct-To-Consumer (DTC) sales channel in the US, offering three of ...

Sarno discusses her favourite memory from Frontiers Health, as well as the importance of equity and accessibility for ...

Earlier this year, PTC Therapeutics and Novartis' experimental therapy for Huntington's, mRNA splicing modifier PTC518 ...

LSX World Congress is a meeting place for biotechs, big pharma companies, and investors. Milenko Cicmil is familiar with all three worlds as CEO of Tasca Therapeutics, an investor with Cure Ventures, ...

The Moderna Innovation and Technology Centre (MITC) in Harwell is the flagship part of a 10-year, £1 billion investment in ...

Roche has staked a claim to use its oral selective oestrogen receptor degrader (SERD) giredestrant as a second-line therapy ...

According to a head-to-head trial called DEVOTE, which underpins the application, the high-dose of nusinersen slowed ...